Voyager Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.4 | $80.0 | $250.0 | $40.9 | $37.4 |
| Operating income | -$131.8 | -$83.3 | $122.0 | -$50.8 | -$73.6 |
| Net income | -$119.7 | -$65.0 | $132.3 | -$46.4 | -$71.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$135.1 | -$18.8 | $74.7 | -$15.0 | -$55.1 |
Shares outstanding 60.4M · Free float 55.4%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.